Targeting KRAS in Non-Small Cell Lung Cancer

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Kirsten Rat Sarcoma viral oncogene homolog (KRAS) is the most frequently altered oncogene in Non-Small Cell Lung Cancer (NSCLC).
• KRAS mutant tumors exhibit unique biology and treatment resistance, historically making KRAS a challenging therapeutic target.
• The discovery of a specific pocket in KRAS G12C enabled the development of direct inhibitors, marking a significant advancement.

Purpose of the Study:

• To review the current landscape of KRAS G12C inhibitors in NSCLC.
• To discuss emerging mechanisms of resistance to KRAS G12C targeted therapies.
• To explore potential combination strategies and the role of co-mutations in optimizing treatment.

Main Methods:

• Literature review of preclinical and clinical studies on KRAS G12C inhibitors.
• Analysis of resistance mechanisms associated with targeted KRAS G12C therapy.
• Evaluation of ongoing clinical trials for combination therapies and immunotherapy in KRAS-mutant NSCLC.

Main Results:

• Direct KRAS G12C inhibitors like sotorasib and adagrasib have shown efficacy but are associated with acquired resistance.
• Mechanisms of resistance include pathway reactivation and co-occurring mutations.
• Clinical trials are investigating novel inhibitors, combination therapies, and immunotherapy approaches.

Conclusions:

• Targeted therapy for KRAS G12C-mutant NSCLC represents a breakthrough, but resistance necessitates further research.
• Combination strategies and consideration of co-mutations are essential for overcoming resistance and improving patient outcomes.
• The optimal first-line treatment strategy for KRAS-mutant NSCLC is likely to involve personalized combination therapies.